Head-to-head dispatch
Layla vs Luvo Health
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…
Marked down on: Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
Desk Score
A multi-program telehealth brand with a full per-4-week price list published for every GLP-1 molecule and route — compounded and brand-name Ozempic, injection and tablet — plus a separate NAD+/sermorelin longevity line, also available.
Marked down on: Price varies significantly by molecule, route and term length — the 4-week rate runs meaningfully higher per week than the 12/24/52-week commitments, a real lock-in tradeoff to weigh before choosing a term
Layla takes this head-to-head with the higher Desk Score, 70/100 (C) against 68/100 (C) for Luvo Health. Luvo Health still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Layla
70/100
C
Luvo Health
68/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Layla | Luvo Health |
|---|---|---|
| Semaglutide | $237/mo (all doses, compounded) | $249/4wk injection ($62/wk); $279/4wk tablets ($70/wk) — compounded, cheaper on longer terms |
| Tirzepatide | $199/mo (all doses, compounded) | $339/4wk injection ($85/wk) — compounded, cheaper on longer terms |
| Coverage | Coverage not published | Coverage not published |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | People wanting oral or injectable semaglutide with a brand-inclusive glp-1 upgrade path. | Shoppers who want compounded and brand GLP-1s, an oral tablet option, and a published price list, and are willing to commit to a longer term to bring the weekly rate down. |
| Desk Score | 70/100C | 68/100C |
The verdict
Desk pick — LaylaLayla takes this head-to-head with the higher Desk Score, 70/100 (C) against 68/100 (C) for Luvo Health. Luvo Health still holds its ground where its strengths line up with yours.
Choose Layla if…
People wanting oral or injectable semaglutide with a brand-inclusive glp-1 upgrade path.
$237/mo (all doses, compounded) sema · $199/mo (all doses, compounded) tirz · Coverage not published
Choose Luvo Health if…
Shoppers who want compounded and brand GLP-1s, an oral tablet option, and a published price list, and are willing to commit to a longer term to bring the weekly rate down.
$249/4wk injection ($62/wk); $279/4wk tablets ($70/wk) — compounded, cheaper on longer terms sema · $339/4wk injection ($85/wk) — compounded, cheaper on longer terms tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Layla · Luvo Health.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Layla vs CoreAge Rx
- Luvo Health vs Vaylen
- Layla vs Strut Health
- Luvo Health vs Ondra Health
- Layla vs Invigor Medical
- Luvo Health vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.